Torrey et al. proved that targeting TNFR2 with antagonistic antibodies inhibits not only proliferation of cancer cells but also proliferation of Tregs infiltrating the tumor while simultaneously inducing the expansion of effector T lymphocytes (195). This evidence concerns the gene TNFRSF1B and neoplasm.